Eli Lilly and Company $LLY Shares Acquired by L & S Advisors Inc

L & S Advisors Inc raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,101 shares of the company’s stock after buying an additional 1,026 shares during the quarter. Eli Lilly and Company comprises 1.3% of L & S Advisors Inc’s portfolio, making the stock its 16th largest position. L & S Advisors Inc’s holdings in Eli Lilly and Company were worth $13,331,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Burling Wealth Partners LLC raised its position in Eli Lilly and Company by 15.7% during the second quarter. Burling Wealth Partners LLC now owns 10,403 shares of the company’s stock valued at $8,109,000 after buying an additional 1,415 shares during the period. Oak Harvest Investment Services boosted its holdings in Eli Lilly and Company by 8.3% in the 2nd quarter. Oak Harvest Investment Services now owns 3,973 shares of the company’s stock valued at $3,097,000 after purchasing an additional 305 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. increased its position in shares of Eli Lilly and Company by 18.8% during the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 41,313 shares of the company’s stock valued at $32,186,000 after purchasing an additional 6,544 shares during the period. Nixon Peabody Trust Co. raised its position in Eli Lilly and Company by 63.6% in the second quarter. Nixon Peabody Trust Co. now owns 19,510 shares of the company’s stock worth $15,209,000 after purchasing an additional 7,588 shares in the last quarter. Finally, Clearstead Trust LLC grew its position in Eli Lilly and Company by 1.2% in the second quarter. Clearstead Trust LLC now owns 4,860 shares of the company’s stock valued at $3,789,000 after acquiring an additional 57 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on LLY. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, November 3rd. Berenberg Bank reiterated a “hold” rating and set a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. JPMorgan Chase & Co. lowered their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, September 16th. Finally, Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research report on Sunday, August 17th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $999.32.

Eli Lilly and Company Trading Up 0.4%

Shares of LLY stock opened at $1,022.00 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,032.95. The company has a market capitalization of $966.19 billion, a PE ratio of 66.80, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The business’s fifty day moving average is $820.93 and its 200 day moving average is $779.85.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the company posted $1.18 EPS. The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.